CN108836974B - Composition for reducing blood sugar and protecting liver based on multipath regulation mechanism - Google Patents
Composition for reducing blood sugar and protecting liver based on multipath regulation mechanism Download PDFInfo
- Publication number
- CN108836974B CN108836974B CN201810499839.2A CN201810499839A CN108836974B CN 108836974 B CN108836974 B CN 108836974B CN 201810499839 A CN201810499839 A CN 201810499839A CN 108836974 B CN108836974 B CN 108836974B
- Authority
- CN
- China
- Prior art keywords
- oligosaccharide
- liver
- composition
- blood sugar
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 210000004369 blood Anatomy 0.000 title claims abstract description 53
- 239000008280 blood Substances 0.000 title claims abstract description 53
- 210000004185 liver Anatomy 0.000 title claims abstract description 46
- 230000001603 reducing effect Effects 0.000 title claims abstract description 31
- 230000002633 protecting effect Effects 0.000 title claims abstract description 17
- 230000008844 regulatory mechanism Effects 0.000 title description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 38
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 33
- 241000405414 Rehmannia Species 0.000 claims abstract description 19
- 150000003272 mannan oligosaccharides Chemical class 0.000 claims abstract description 18
- 230000000694 effects Effects 0.000 abstract description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 12
- 230000000968 intestinal effect Effects 0.000 abstract description 9
- 241001289435 Astragalus brachycalyx Species 0.000 abstract description 5
- 235000002917 Fraxinus ornus Nutrition 0.000 abstract description 5
- 230000007246 mechanism Effects 0.000 abstract description 4
- 210000003484 anatomy Anatomy 0.000 abstract description 3
- 238000012423 maintenance Methods 0.000 abstract 1
- 235000013305 food Nutrition 0.000 description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 206010012601 diabetes mellitus Diseases 0.000 description 14
- 239000008103 glucose Substances 0.000 description 13
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 8
- 230000003908 liver function Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000007873 sieving Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108010006464 Hemolysin Proteins Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 235000020828 fasting Nutrition 0.000 description 4
- 239000003228 hemolysin Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000004347 intestinal mucosa Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 210000004258 portal system Anatomy 0.000 description 3
- 210000003240 portal vein Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000001839 systemic circulation Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 2
- 235000020927 12-h fasting Nutrition 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229920002581 Glucomannan Polymers 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010061481 Renal injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940046240 glucomannan Drugs 0.000 description 2
- 230000004110 gluconeogenesis Effects 0.000 description 2
- 108091005995 glycated hemoglobin Proteins 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 208000037806 kidney injury Diseases 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical group COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- HSSYVKMJJLDTKZ-UHFFFAOYSA-N 3-phenylphthalic acid Chemical group OC(=O)C1=CC=CC(C=2C=CC=CC=2)=C1C(O)=O HSSYVKMJJLDTKZ-UHFFFAOYSA-N 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000405911 Rehmannia glutinosa Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- RNBGYGVWRKECFJ-ZXXMMSQZSA-N alpha-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ZXXMMSQZSA-N 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 229940025237 fructose 1,6-diphosphate Drugs 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000004121 glycogenesis Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 239000012856 weighed raw material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a composition for reducing blood sugar and protecting liver, which at least comprises, by weight, 20-80 parts of rehmannia root oligosaccharide and 20-80 parts of mannan oligosaccharide. The invention simultaneously uses the rehmanniae oligosaccharide and the manna oligosaccharide, and enables the intestinal-hepatic axis to mutually influence under various mechanisms through the anatomical structure and the function of the intestinal tract and the liver and the intestinal microecological balance to form strong balance, synergy and synergy effects, so that the blood sugar reducing effect, the normal blood sugar level maintenance and the liver protection effect of the invention are obviously improved compared with the single use of the rehmanniae oligosaccharide or the single use of the manna oligosaccharide.
Description
Technical Field
The invention belongs to the field of medical treatment, health care and food, and particularly relates to a composition for reducing blood sugar and protecting liver based on a multipath regulation mechanism.
Background
Safety and health are the focus of world concerns in the 21 st century. Diabetes mellitus is the third place after tumor and cardiovascular and cerebrovascular diseases and is one of chronic diseases seriously harming human health. Diabetes is a syndrome of metabolic disorders of carbohydrates, lipids and proteins caused by insufficient insulin secretion or insulin resistance of the body. The diabetes causes fat metabolism disorder, influences liver function, causes liver enlargement, abnormal liver function and even causes liver cirrhosis. The main treatment methods for diabetes at home and abroad are manual insulin injection or oral hypoglycemic drugs, but the treatment methods have the problems that the dosage is difficult to accurately adjust, the drug effect is difficult to predict, the patients suffer from great pain, the toxic and side effects are strong, and the liver and kidney are easily damaged.
The liver is a central organ of the body's metabolism and plays an important regulatory role in gluconeogenesis, glycogen synthesis, storage, and uptake, utilization, and release of glucose as an energy source. The sugar metabolism of the liver not only supplies energy for its own physiological activities, but also supplies glucose for the energy needs of other organs. Liver is closely related to blood sugar abnormality, and related documents report that liver insulin resistance can cause fasting hyperglycemia; the liver cirrhosis patients have abnormal glucose metabolism; patients with fatty liver can have obvious insulin resistance; acute severe hepatitis patients are easy to cause hepatic hyperglycemia, and blood sugar is recovered to be normal along with the recovery of liver function, so that the liver plays an important role in glycometabolism and is closely related to diabetes.
The intestinal mucosa forms the first line of defense for the human body to contact with exogenous substances, and the liver forms the second line of defense for the human body. The gut and liver are closely related in embryonic origin and anatomical relationship, with the embryonic origin of both organs being identical, i.e., the foregut, and precursors of gut-associated lymphocytes originating from the developing liver. The two organs are anatomically connected with each other through a portal vein, about 80% of blood of the liver comes from the portal vein, intestinal mucosa lymphocytes migrate between the liver and the intestinal tract to defend pathogens and penetrate through an intestinal mucosa barrier to reach the liver, and the immune response of the intestinal tract releases a large amount of proinflammatory cytokines which can enter the liver through the portal vein; meanwhile, the liver has a certain regulation function on intestinal tract-derived lymphocytes. When the function of intestinal lymphocyte is disordered, the pathological changes of liver and intestine and the related complications can be caused, and the intestinal-hepatic axis related to anatomy and function is formed.
Under normal conditions, beneficial substances such as acetic acid, butyric acid, hormone and the like can be secreted by the beneficial intestinal flora, the content of endotoxin is greatly reduced, and the beneficial substances enter the liver through a portal system along with the blood flow of the intestinal tract and then enter the systemic circulation to promote the normal physiological metabolism of the human body. When the intestinal flora is disordered, the permeability of intestinal mucosa is increased, the barrier function of the intestinal tract is reduced, harmful bacteria can be massively propagated and cracked, and a large amount of endotoxin is secreted, enters a portal system, reaches the liver, enters systemic circulation and finally induces various diseases.
The intestinal tract and the liver are balanced in the micro-ecology of the intestinal tract through the anatomical structure and the function, so that the intestinal-hepatic axis is influenced mutually under various mechanisms.
Konjak Glucomannan (KGM) is heteropolysaccharide formed by combining D-glucose and D-mannose through beta-1, 4 glycosidic bonds, and the average polymerization degree of sugar molecules is between 1000 and 10000. Because KGM has the defects of high molecular polymerization degree, high viscosity, low solubility and the like, the application of natural KGM is limited to a certain extent. KGM can be degraded to generate glucomannan with different polymerization degrees, wherein, the mannan oligosaccharide is a kind of saccharide with lower polymerization degree, the polymerization degree of saccharide molecules is 2-10 saccharides, and the KGM is widely applied to the fields of food, chemical industry, medicine and the like.
Some recent pharmacodynamic experiments and clinical experiments show that the mannooligosaccharide can regulate intestinal flora disorder and has the effects of reducing blood sugar and blood fat.
In addition, a special medical food for diabetes mellitus has the functions of reducing blood sugar and improving liver functions, and is particularly urgent and important for patients suffering from liver diseases and diabetes mellitus.
Disclosure of Invention
The invention aims to solve the technical problem of providing a composition for reducing blood sugar and protecting liver, which at least comprises rehmannia root oligosaccharide and mannan oligosaccharide. Meanwhile, the rehmannia root oligosaccharide and the mannooligosaccharide form strong balance, synergy and synergy effects through an intestinal and hepatic axis mechanism, so that the blood sugar reducing effect and the liver protecting effect of the composition are obviously improved compared with the effect of singly using the rehmannia root oligosaccharide or singly using the mannooligosaccharide.
The technical scheme adopted by the invention for solving the technical problems is as follows:
a composition for reducing blood sugar and protecting liver at least comprises, by weight, 20-80 parts of rehmannia root oligosaccharide and 20-80 parts of mannan oligosaccharide.
In a further technical scheme, the blood sugar reducing and liver protecting composition comprises 60 parts by weight of rehmannia root oligosaccharide and 40 parts by weight of mannan oligosaccharide.
In the technical scheme of the invention, the sources of the rehmannia root oligosaccharide are as follows: purchased from pioneer, shanxi pannier biotechnology limited, and detected by HPLC, and has the content of 80 percent.
In the technical scheme of the invention, the sources of the manna oligosaccharide are as follows: the inventor prepares according to the method of Chinese invention patent CN201110305324.2, and detects by liquid chromatography and mass spectrometry, total sugar: ≧ 99.5%; functional components of mannose 2-mannose 10: ≧ 98.0%; wherein the content of mannose 4-mannose 8 is more than 85%.
In one embodiment, the composition of the invention is used in a special medical formula.
According to the requirements of the general rule of formula food for special medical use, the invention also provides a non-full nutritional formula food for reducing blood sugar and protecting liver by combining the physical characteristics of diabetics, which comprises the following components in parts by weight: 42g of rehmannia root oligosaccharide, 28g of mannan oligosaccharide, 10g of collagen peptide, 10g of various amino acids, 6g of various vitamins and 4g of various minerals.
The preparation method of the non-full nutritional formula food for reducing blood sugar and protecting liver comprises the following steps:
(1) sterilizing each component by adopting ultraviolet irradiation;
(2) sieving the components with a 60-mesh sieve, and then weighing the components in the formula according to the weight;
(3) putting the weighed components into a mixer together, uniformly mixing, and sieving by a 60-mesh sieve;
(4) and (5) quantitatively subpackaging the mixed product according to the required specification.
All operations need to be carried out in a clean environment required by the Specification for good production of formula food for special medical use.
The product prepared by the invention has the following advantages:
(1) the composition comprises 60 parts by weight of rehmannia root oligosaccharide and 40 parts by weight of mannan oligosaccharide, is suitable for the field of food, medicines or health care products, and is used for reducing the blood sugar concentration of diabetics.
(2) The composition of the invention uses the rehmannia root oligosaccharide and the mannan oligosaccharide simultaneously.
The rehmanniae radix oligosaccharide can improve damaged pancreatic tissue, regulate insulin and its hormone secretion, increase liver glycogenesis, and reduce gluconeogenesis by reducing glucose phosphatase activity, thereby further reducing blood sugar.
The mannooligosaccharide has the effects of proliferating beneficial bacteria and inhibiting harmful bacteria, when the number of beneficial bacteria groups such as bifidobacteria, bacteroids, lactobacilli and the like in intestinal tracts is obviously increased, the intestinal microorganisms can secrete a large number of beneficial substances such as acetic acid, butyric acid, protein, hormone and the like, the content of endotoxin is greatly reduced, the substances enter systemic circulation after entering the liver through a portal system along with the blood flow of the intestinal tracts, and the acetic acid and the butyric acid improve the glucose balance in vivo by inducing glucagon-like peptide-1 (GLP-1) and polypeptide YY (PYY), so that the blood glucose concentration of a type II diabetic patient is effectively reduced.
The rehmanniae oligosaccharide and the mannanoligosaccharide achieve the purpose of jointly reducing blood sugar through different action ways, and when the rehmanniae oligosaccharide and the mannanoligosaccharide are combined together, the rehmanniae oligosaccharide and the mannanoligosaccharide have strong balancing, synergistic and synergistic effects, so that the blood sugar reducing effect is improved and stabilized.
(3) The rehmannia root oligosaccharide selected by the composition has the liver protection effect, and the mannan oligosaccharide influences the liver metabolism by regulating the balance of intestinal flora to form an intestinal-hepatic axis mechanism related to the intestinal microecological balance. Therefore, the composition of the invention not only has the obvious effect of reducing blood sugar, but also has good liver protection function, and the double synergistic effect has special health care and clinical significance for patients suffering from liver diseases and diabetes mellitus. The reason is that the medicines are required to be taken for a long time at present for improving the liver function and reducing the blood sugar concentration, the medicines for the two diseases conflict with each other, when the patients with diabetes mellitus complicated with liver and kidney injury take the medicines, the conditions of difficult adjustment of dosage, difficult measurement of effect and the like can be met, and once the liver and kidney injury occurs, a plurality of oral hypoglycemic medicines cannot be used, so that the treatment method is often lost, and the problem of the complicated liver function of the diabetes patients in China is more serious than that of the other countries.
(4) The composition of the invention is applicable to the fields of food, medicine or health care products, and is used for reducing the blood sugar concentration of a type II diabetes patient and simultaneously improving the liver function of the patient.
(5) The non-full nutritional formula food for reducing blood sugar and protecting liver provided by the invention can improve liver function while reducing blood sugar. The food can be taken for a long time, and has no side effect on human body, which is particularly urgent and important for patients suffering from liver diseases and diabetes.
Detailed Description
Example 1
A composition for lowering blood sugar and protecting liver comprises rehmanniae radix oligosaccharide and mannooligosaccharide, and the composition ratio can be the following combination, as shown in Table 1:
TABLE 1
| Group of | Rehmannia root oligosaccharide (parts by weight) | Mannan oligosaccharide (parts by weight) |
| Composition A | 20 | 80 |
| Composition B | 80 | 20 |
| Composition C | 50 | 50 |
| Composition D | 60 | 40 |
The rehmannia glutinosa oligosaccharide is from: purchased from pioneer, shanxi pannier biotechnology limited, and detected by HPLC, and has the content of 80 percent.
The sources of the mannanoligosaccharide are as follows: the inventor prepares according to the method of Chinese invention patent CN201110305324.2, and detects by liquid chromatography and mass spectrometry, total sugar: ≧ 99.5%; functional components of mannose 2-mannose 10: ≧ 98.0%; wherein the content of mannose 4-mannose 8 is more than 85%.
The preparation method of the composition containing the components and having the functions of reducing blood sugar and protecting liver comprises the following steps:
(1) firstly, the rehmannia root oligosaccharide and the mannan oligosaccharide are sterilized by ultraviolet irradiation,
(2) sieving the raw materials with a 60-mesh sieve, and weighing the components in the formula for later use;
(3) putting the weighed raw materials into a mixer together, uniformly mixing, and sieving by a 60-mesh sieve;
(4) and quantitatively subpackaging the obtained product according to the required specification.
Example 2
The hypoglycemic and hepatoprotective composition prepared in example 1 was used to examine the hypoglycemic and hepatoprotective effects of the composition on mice through experiments.
Efficacy test-hypoglycemic efficacy test
Selecting healthy rats with similar sizes and forms, adaptively feeding for a week, fasting for 12h, performing intraperitoneal injection on STZ (dissolved in 0.1 mol/L citric acid-sodium citrate buffer solution with pH 4.5, prepared in situ under the conditions of light-shielding and ice-bath storage) at a concentration of 120mg/kg at one time, cutting off the tail after 3 days, and taking blood to measure blood sugar, wherein the blood sugar value is not less than 14.2mmol/L, and the diabetes molding is considered to be successful. Rats successfully molded were randomly divided into 5 groups of 10 rats each, namely a model group, a metformin group, a rehmanniae oligosaccharide group, a mannooligosaccharide group, a composition A group, a composition B group, a composition C group and a composition D group. Another 10 healthy rats in the same batch are taken as a normal control group, and the group is intragastrically administered on the same day, wherein the normal group and the model group are as follows: purified water, the rest groups are 200mg/kg.d,
continuously administering for 30 days, feeding the rats 10 days and 20 days after molding, fasting for 12h, and measuring fasting blood glucose; after 60 days and 90 days of continuous administration, blood was taken through the femoral artery, and upper serum was extracted to measure the glycated hemoglobin value. The glycosylated hemoglobin is formed by non-enzymatic combination of hemoglobin (Hb) and saccharides (such as glucose, glucose-6-phosphate or fructose-1, 6-diphosphate), the synthesis process is slow and irreversible, the concentration of the glycosylated hemoglobin is related to the service life of red blood cells (average 120 days) and the average concentration of blood glucose in the period, the glycosylated hemoglobin is not changed by fluctuation of the blood glucose concentration of plasma every day and is not influenced by exercise or food, so the glycosylated hemoglobin reflects the average blood glucose concentration of the past 6-10 weeks, and a reliable index (the content of normal glycosylated hemoglobin is 4-6% of the total hemoglobin) can be provided for evaluating the control condition of blood glucose. The results of the tests are shown in Table 2 below:
TABLE 2
Note: each administration group was compared with the model group, P < 0.05, P < 0.01
The blood sugar and the glycosylated hemoglobin values of the rats in the normal group have no obvious change.
After the diabetic rats are treated, the fasting blood glucose value and the glycosylated hemoglobin value of the rats in each administration group are remarkably and extremely remarkably reduced.
The composition group formed by combining the rehmanniae oligosaccharide and the manna oligosaccharide has strong balance, synergy and synergy effects, the blood sugar reducing effect of the composition group is more obvious than that of the rehmanniae oligosaccharide and the manna oligosaccharide, and the effect of the composition group D is extremely obvious.
The composition A group, the composition B group and the composition C group which are formed by combining the rehmanniae oligosaccharide and the mannooligosaccharide have the similar blood sugar reducing effect with the drug control group metformin. The fasting blood glucose value and the glycosylated hemoglobin value of the rats in the composition D group measured last time are lower than those in the metformin drug control group, which indicates that the composition D group has obvious blood glucose reducing effect. The glycated hemoglobin values of the composition group D approached normal values 90 days after administration of the composition to rats. The composition group D can not only reduce fasting blood sugar, but also effectively control blood sugar, so that the blood sugar is kept at a stable normal level for a long time.
Efficacy experiment two liver protection efficacy experiments
60 ICR mice are selected as experimental animals to carry out the experiment of the liver injury animal model, the experimental animals are randomly divided into 6 groups, namely a blank control group, a model group, a bifendate group, a rehmannia root oligosaccharide group, a mannan oligosaccharide group, a composition A group, a composition B group, a composition C group and a composition D group, each experimental group is perfused once a day according to the dose shown in the table 3 for 6 days continuously, the blank control group and the model group are administered with purified water in the same amount, after the administration on the 6 th day, the blank control group is subcutaneously injected with physiological saline in the same amount, other components are respectively injected with 0.5 percent of carbon tetrachloride 10ml/kg of body weight, after 4 hours, each experimental group is administered once again, the animals are killed after the administration for 1 hour on the 7 th day, blood is taken to determine the serum hemolysin content, the thymus and the spleen are respectively weighed to calculate the liver index, and the result is shown:
TABLE 3
| Group of | Dosage form | Hemolysin | Thymus index g/10g | Spleen index g/10g |
| Blank control group | - | 0.411±0.08* | 61.23±5.43** | 81.26±8.88** |
| Model set | - | 0.258±0.09 | 31.81±4.67 | 38.74±9.02 |
| Biphenyldicarboxylate group | 5mg/kg | 0.401±0.08* | 39.84±4.75* | 67.21±8.47** |
| Rehmannia root oligosaccharide group | 0.5g/kg | 0.347±0.10* | 36.55±4.49 | 52.44±9.89* |
| Manno-oligosaccharides group | 0.5 g/kg | 0.338±0.09* | 34.66±4.82 | 50.19±7.56* |
| Composition group A | 0.5g/kg | 0.379±0.08* | 37.68±4.43* | 57.71±8.01* |
| Composition group B | 0.5g/kg | 0.400±0.09* | 39.08±4.55* | 63.02±8.21** |
| Composition group C | 0.5g/kg | 0.396±0.07* | 38.85±4.31* | 58.11±8.09* |
| Composition group D | 0.5 g/kg | 0.402±0.06* | 41.12±3.83* | 65.97±7.89** |
Note: each group was compared to the model group, P < 0.05, P < 0.01
Test results show that the serum hemolysin content, thymus index and spleen index of the blank control group mouse are remarkably increased compared with those of the model group, and the success of molding is shown; compared with the model group, the serum hemolysin content and the spleen index of the mice are obviously increased in each administration group, and the thymus index is obviously increased in each administration group except the rehmanniae oligosaccharide group and the mannooligosaccharide group; the liver protection effect of the composition group A, the composition group B, the composition group C and the composition group D is more obvious than the effect of the single rehmannia root oligosaccharide and the single mannooligosaccharide, and the combination of the rehmannia root oligosaccharide and the mannooligosaccharide has strong balance, synergy and synergy; all of the composition group A, composition group B, composition group C and composition group D also had equal or similar efficacy in enhancing the immune function of liver-injured mice as compared with the positive control, bifendate group.
Example 3
According to the requirements of the general rule of formula food for special medical use, and in combination with the physical characteristics of diabetics, a non-full-nutrition formula food for reducing blood sugar and protecting liver comprises the following components in parts by weight: 42g of rehmannia root oligosaccharide, 28g of mannan oligosaccharide, 10g of collagen peptide, 10g of various amino acids, 6g of various vitamins and 4g of various minerals.
The preparation method of the non-full nutritional formula food for reducing blood sugar and protecting liver comprises the following steps:
(1) sterilizing each component by adopting ultraviolet irradiation;
(2) sieving the components with a 60-mesh sieve, and then weighing the components in the formula according to the weight;
(3) putting the weighed components into a mixer together, uniformly mixing, and sieving by a 60-mesh sieve;
(4) and (5) quantitatively subpackaging the mixed product according to the required specification.
All operations need to be carried out in a clean environment required by the Specification for good production of formula food for special medical use.
The taking method comprises the following steps: the non-full nutritional formula food for reducing blood sugar and protecting liver is dissolved in a proper amount of warm water and can be drunk.
The above description is not intended to limit the present invention, and the present invention is not limited to the above examples. Those skilled in the art should also realize that changes, modifications, additions and substitutions can be made without departing from the true spirit and scope of the invention. .
Claims (1)
1. The composition for reducing blood sugar and protecting liver is characterized by consisting of 60 parts by weight of rehmannia root oligosaccharide and 40 parts by weight of mannan oligosaccharide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810499839.2A CN108836974B (en) | 2018-05-23 | 2018-05-23 | Composition for reducing blood sugar and protecting liver based on multipath regulation mechanism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810499839.2A CN108836974B (en) | 2018-05-23 | 2018-05-23 | Composition for reducing blood sugar and protecting liver based on multipath regulation mechanism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108836974A CN108836974A (en) | 2018-11-20 |
| CN108836974B true CN108836974B (en) | 2020-09-29 |
Family
ID=64213282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810499839.2A Active CN108836974B (en) | 2018-05-23 | 2018-05-23 | Composition for reducing blood sugar and protecting liver based on multipath regulation mechanism |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108836974B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101649335A (en) * | 2009-06-25 | 2010-02-17 | 中国食品发酵工业研究院 | Preparation method of high-purity alpha-1,6 trisaccharide |
| CN105982009A (en) * | 2015-02-05 | 2016-10-05 | 骆奇 | Composition for regulating human body intestinal micro-ecology |
-
2018
- 2018-05-23 CN CN201810499839.2A patent/CN108836974B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101649335A (en) * | 2009-06-25 | 2010-02-17 | 中国食品发酵工业研究院 | Preparation method of high-purity alpha-1,6 trisaccharide |
| CN105982009A (en) * | 2015-02-05 | 2016-10-05 | 骆奇 | Composition for regulating human body intestinal micro-ecology |
Non-Patent Citations (2)
| Title |
|---|
| 地黄多糖和寡糖的药理作用研究进展;王君明 等;《中国老年学杂志》;20151130;第35卷(第22期);第6603-6605页 * |
| 酶法制备甘露低聚糖;康立新 等;《食品科技》;20121231;第37卷(第7期);第237-239页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108836974A (en) | 2018-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2011500B1 (en) | Fat accumulation inhibitor for the treatment of metabolic syndrome | |
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN102526479B (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| ZA200506723B (en) | Composition for treating hepatitis C | |
| CN102511712A (en) | Xylo-oligosaccharide-containing healthcare food auxiliary for blood sugar reduction | |
| CN108836974B (en) | Composition for reducing blood sugar and protecting liver based on multipath regulation mechanism | |
| CN110721203A (en) | Application of combination of bifidobacterium and berberine in treating pre-diabetes and type2 diabetes | |
| JP5897796B2 (en) | Hypoglycemic agent and food and drink for preventing diabetes or improving symptoms comprising the same | |
| CN112971154A (en) | Solid mixture rich in water-soluble dietary fibers and alpha-amylase inhibitor, and preparation method and application thereof | |
| EP3574912B1 (en) | Composition for treating diabetic disease | |
| CN112544844A (en) | Rhizoma polygonati solid beverage with blood glucose reducing effect and preparation method thereof | |
| EP2668851A1 (en) | Liver function-improving agent | |
| BUTNARIU | Biochemical aspects of diabetes mellitus | |
| TWI678211B (en) | Uses of cistanche tubulosa extract and isoacteoside in protecting muscles | |
| CN112494502B (en) | Saccharide composition for replenishing blood in blood deficiency syndrome | |
| CN100528186C (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN110613792B (en) | Traditional Chinese medicine composition with blood sugar reducing effect and preparation method and application thereof | |
| CN116585329A (en) | Application of alemtic acid in preparation of medicines for treating hepatitis and pulmonary fibrosis | |
| WO2021007933A1 (en) | Application of maggots in treatment of diabetes | |
| CN111631398A (en) | Food composition with blood sugar and blood fat reducing effects, preparation method and application thereof | |
| CN104784192A (en) | Application of clam meat oligosaccharide in preparation of hypoglycemic drugs and preparation method of clam meat oligosaccharide | |
| CN115531482B (en) | Application of ginseng body-building oral liquid in preparation of medicine for preventing and treating hypoalbuminemia | |
| CN113133531A (en) | Compound protein supplement and preparation method thereof | |
| TWI698244B (en) | Use of a combination of small-molecule fucoidan and fucoxanthin for preparing a composition for improving non-alcoholic fatty liver | |
| CN111345422A (en) | Solid beverage with synergistic blood sugar reducing effect and preparation and eating method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |